



राष्ट्रीय पशु जैव प्रौद्योगिकी संस्थान National Institute of Animal Biotechnology

(An Autonomous Institute of the Department of Biotechnology, Ministry of Science and Technology, Government of India)



Dr. MK Bhan Memorial Lecture By

Prof. Sudhanshu Vrati, Former ED, RCB, Faridabad
Title: Making of the Indian Rotavirus Vaccine

Dr Krishna Ella, CEO, Bharat Biotech, Hyderabad

Title: Inspiration of Startup & Innovation journey
with Dr Bhan

Date & Venue

December 17, 2024 @ 2 P. M. in MK Bhan Auditorium

BRIC-NIAB

Programme



02:00 to 02:05 PM: Welcome note by Dr Madhuri Subbiah,

Scientist, NIAB

02:05 to 02:10 PM: Tribute to late Dr. MK Bhan by

Dr. G. Taru Sharma, Director, NIAB & guests

02:10 to 02:15 PM: Address by Dr. G. Taru Sharma, Director, NIAB

02.15 to 02.20 PM: Introduction of Prof. Sudhanshu Vrati by Dr

Madhuri Subbiah, Scientist, NIAB

02.20 to 02.25 PM: Introduction of Dr Krishna Ella, CEO, Bharat

Biotech, Hyderabad by Dr Madhuri Subbiah

Scientist, NIAB

02:25 to 04:25 PM: Dr. MK Bhan Memorial Lecture by Prof.

Sudhanshu Vrati, Former Executive Director, RCB, Faridabad on "Making of the Indian Rotavirus Vaccine" & Dr Krishna Ella, CEO, Bharat Biotech, Hyderabad on

"Inspiration of Startup & Innovation journey

with Dr Bhan".

04:25 to 04:35 PM: Felicitation to Speakers by Director, NIAB

04:35 to 04:45 PM: Vote of thanks

04:45 PM onwards: High tea

YouTube Channel link https://www.youtube.com/channel/UCGfwWgfR tQPgSG2pE-fy Q

BRIC-NIAB

About the speaker



Prof. Sudhanshu Vrati Former Executive Director, RCB, Faridabad

Prof. Sudhanshu Vrati is a renowned virologist and an esteemed leader in the field of biotechnology, recognized for his pioneering contributions to virology, molecular biology, and vaccine development. He served as the Executive Director of the Regional Centre for Biotechnology (RCB), Faridabad, where he played a transformative role in shaping the institute into a premier center for advanced research, innovation, and education in the life sciences.

Prof. Vrati's academic journey began with an undergraduate degree in microbiology, followed by advanced studies in molecular biology and virology at some of the world's most prestigious institutions. He earned his PhD in Biochemistry from The Australian National University, Canberra. He holds a DIIT in Biochemical Engineering from the Indian Institute of Technology Delhi and an MSc in Microbiology from G. B. Pant University of Agriculture and Technology, Pantnagar. Dr. Vrati conducted post-doctoral research at CSIRO Molecular Sciences, Sydney, and served as a Visiting Scientist at the Pasteur Institute, Paris. His career has been defined by significant contributions to the development of vaccines and therapeutic interventions against viral diseases, with a particular focus on addressing public health challenges in India and beyond. His work in vaccine development, including research on RNA viruses and their replication mechanisms, has earned him national and international acclaim.

As a visionary leader, Dr. Vrati emphasized fostering interdisciplinary research at RCB, facilitating collaborations with national and international organizations, and promoting translational research to address societal needs. Under his stewardship, RCB became a hub for training and mentoring young scientists, equipping them with the skills and knowledge to drive innovation in biotechnology.

Dr. Vrati has been an active member of numerous scientific committees and advisory boards, contributing his expertise to the formulation of research policies and strategies to strengthen India's scientific ecosystem. He is an elected fellow of the National Academy of Sciences, Indian National Science Academy, and the Indian Academy of Sciences. The Department of Biotechnology awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences in 2003. His achievements have been recognized with several prestigious awards and honors, highlighting his enduring impact on virology and biotechnology research.

About the speaker



Dr Krishna Ella CEO, Bharat Biotech, Hyderabad

Dr. Krishna Ella is a distinguished Indian scientist, entrepreneur, and a leading figure in biotechnology, celebrated for his groundbreaking contributions to vaccine development and global public health. He is the founder and chairman of Bharat Biotech International Limited, a pioneering biotechnology company known for its innovation in developing affordable and effective vaccines. Dr. Ella's leadership was instrumental in the development of Covaxin, India's first indigenous COVID-19 vaccine, which played a crucial role in the nation's fight against the pandemic.

Born in Tamil Nadu, Dr. Ella pursued his undergraduate studies in agricultural sciences at the Tamil Nadu Agricultural University and further specialized in plant pathology at the University of Agricultural Sciences, Bangalore. He later completed his Ph.D. in molecular biology at the University of Wisconsin-Madison, USA, where he laid the foundation for his expertise in biotechnology. Driven by a passion for translational research, he established Bharat Biotech in 1996 with the aim of addressing unmet healthcare needs through innovation.

Under his visionary leadership, Bharat Biotech has developed over 20 vaccines, including those for rotavirus, typhoid, and chikungunya, earning recognition for its cutting-edge R&D capabilities. Dr. Ella has been an advocate for affordable healthcare solutions, ensuring that life-saving vaccines are accessible to people worldwide, especially in low- and middle-income countries.

A recipient of numerous national and international awards, Dr. Ella's contributions have elevated India's stature in the global biotechnology arena. He is also a strong proponent of fostering industry-academia collaboration and investing in research that bridges science and public health. Beyond his professional achievements, Dr. Ella's commitment to ethical practices and scientific excellence continues to inspire future generations of scientists and entrepreneurs.

BRIC-NIAB